IBI3010 / Innovent Biologics - LARVOL DELTA

Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors (AACR 2025) - "Although mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate (ADC) with a microtubule inhibitor, has been approved from the FDA for the treatment of FRα-expressing platinum-resistant ovarian cancer. In the GLP toxicology study, IBI3010 was tolerated in cynomolgus monkeys at all dose levels, with the highest dose of 60 mg/kg, defined as the highest non-severely toxic dose (HNSTD). Our findings support the clinical development of IBI3010 to evaluate its potential as an ADC therapeutic for FRα-expressing solid tumors."

Late-breaking abstract • Preclinical • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

Topic: Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors (PRNewswire) - "Innovent Biologics...announces that preclinical data...from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025....IBI3010 shows superior cytotoxicity and bystander effect versus mirvetuximab soravtansine (IMGN853) in vitro. IBI3010 demonstrated superior antitumor activity to IMGN853 in FRα-expressing CDX models, particularly in low-FRα expression models. GLP tox studies in cynomolgus monkeys established 60 mg/kg as HNSTD with full tolerability. These data support the clinical development of IBI3010 to evaluate its potential as an ADC therapeutic for FRα-expressing solid tumors."

Preclinical • Solid Tumor

Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting (PRNewswire) - "Innovent Biologics...announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025."

Preclinical • Oncology